Coronavirus disease pandemic has created a public health havoc worldwide. In. view of the mandatory lockdown in majority of countries, it also has caused a great economic crisis. The Spanish Flu of 1918, infected quarter of the global population (500 million) and killed 50 million individuals. No pandemic in the history of this planet, has caused as much panic, fear, anxiety, and frustration as the coronavirus disease. The Covid-19 is affecting 212 countries and territories around the world. Antarctica is the only continent not yet reached by the 2019-20 coronavirus pandemic. At the time of this writing there are more than 3.8 million cases worldwide, with 270,000 reported deaths. Ranking according to the number of infections is as follows: USA (1.2 million), Spain (216,582), Italy (207,428, UK (182, 260), Germany (164, 316), France (130, 185), Russia (124, 054), Turkey (122, 392), Iran (96, 448), Brazil (92, 630) and China (82, 875). Despite this ranking for number of infections, the ranking for the of deaths is quite different; USA (73,667), United Kingdom (30,076), Spain (25,857), Italy (29, 684), France (24, 594), Germany (6,735), There are so many facts related to the COVID-19 infection, that cannot be described rationally. For instance, Italy’s case fatality rate (CFR) is ten times higher than Germany’s (BBC News). The ranking for CFR is as follows: Italy (11.39), UK (8.17), China (4.05), USA (1.92), South Korea (1.66), Germany (1.0). At the time of this writing, we will have to analyze the infection rate, number of deaths, disparities related to the geography, ethnicity, and comorbidities separately for each country. No generalizations can be made with any degree of accuracy. Although experts’ say that it’s too early to determine, what role different healthcare systems play, in the severity of the COVID-19 pandemic, it’s undeniable that each country’s health care structural organizations, influence its public health response, when faced with such unprecedented virus disease pandemic.

References

1. Zhou P., et al. “A pneumonia outbreak associated with a new coronavirus of probable bat origin”. Nature 579 (2020): 270-273.
2. Sungnak W., et al. “SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes”. Nature Medicine (2020).
3. Yancy CW. “COVID-19 and African Americans”. The Journal of the American Medical Association (2020).
4. Richardson S., et al. “Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with covid-19 in the New York city area”. The Journal of the American Medical Association (2020).
5. Guan W., et al. “Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis”. European Respiratory Journal (2020).
6. Fang L., et al. “Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet”. Lancet4 (2020): E21.
7. Vaduganathan M., et al. “Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19”. The New England Journal of Medicine 17 (2020): 1653-1659.
8. Bonow RO., et al. “Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality”. The Journal of the American Medical Association Cardiology (2020).
9. Shi S., et al. “Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China”. The Journal of the American Medical Association Cardiology (2020).
10. Guo T., et al. “Cardiovascular implications of fatal outcomes of patients with corona virus disease 2019(COVID-19) ”. The Journal of the American Medical Association Cardiology (2020).
11. Coagulopathy and antiphospholipid antibodies in patients with Covid-19”. The New England Journal of Medicine 382 (2020): e38.
12. Brandon MH., et al. “Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hyper coagulopathy and microvascualr immunothrombosis”. Clinica Chimica Acta 507 (2020): 167-173.
13. Merad M and Martin JC. “Pathological inflammation in patients with COVID-19: a key role of monocytes and macrophages”. Nature Reviews Immunology (2020).
14. Kollias A., et al. “Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence for call for action”. Journal of the British Society for Haematology (2020).
15. Bikdeli B., et al. “COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic therapy, and follow-up”. Journal of the American College of Cardiology 5 (2020): 531-538.
16. Granlinski LE., et al. “Mechanisms of Severe Acute Respiratory Syndrome Coronavirus-Induced Acute Lung Injury”. mBio4 (2013): e00271-e00213.
17. Tang N., et al. “Anticoagulant treatment is associated with decreased mortality in severe coronavirus dieses 2019 patients with coagulopathy”. Journal of Thrombosis and Haemostasis 5 (2020): 1094-1099.
18. Barnes BJ., et al. “Targeting potential drivers of Covid-19: Neutrophil extracellular traps”. Journal of Experimental Medicine 6 (2020): e20200652.
19. Thachil J., et al. “ISTH interim guidance on recognition and management of coagulopathy in Covid-19”. Journal of Thrombosis and Haemostasis 5 (2020).
20. Agnelli G., et al. “Apixaban for the treatment of venous thromboembolism associated with cancer”. The New England Journal of Medicine 382 (2020): 1599-1607.
21. Zhong X., et al. “The outcomes of hyperbaric oxygen therapy to retrieve hypoxemia of severe novel coronavirus pneumonia: first case report”. Zhonghua Hanghai Yixue yu Gaoqiya Yixue Zazhi (2020).
22. Harch P. “Hyperbaric oxygen treatment of novel coronavirus (COVID-19) respiratory failure”. Medical Gas Research (2020).